A review and update on the diagnosis and treatment of neuropsychiatric Wilson disease

References

• Merle U, Schaefer M, Ferenci P, et al. Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut. 2007;56:115–120.
   PubMed Web of Science ®Google Scholar
• Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P–type ATPase similar to the Menkes gene. Nat Genet. 1993;5:327–337.
   PubMed Web of Science ®Google Scholar
• Linz R, Lutsenko S. Copper-transporting ATPases ATP7A and ATP7B: cousins, not twins. J Bioenerg Biomembr. 2007;39:403–407.
   PubMed Web of Science ®Google Scholar
• La Fontaine S, Mercer JFB. Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis. Arch Biochem Biophys. 2007;463:149–167.
   PubMed Web of Science ®Google Scholar
• Yaozong CA, Pernilla Wittung-Stafshede L. The six metal binding domains in human copper transporter, ATP7B: molecular biophysics and disease-causing mutations. BioMetals. 2017; 30:823–840.
   Web of Science ®Google Scholar
• Qian Y, Tiffany-Castiglioni E, Welsh J, et al. Copper efflux from murine microvascular cells requires expression of the menkes disease Cu-ATPase. J Nutr. 1998;128:1276–1282.
   PubMed Web of Science ®Google Scholar
• Fu X, Zhang Y, Jiang W, et al. Regulation of copper transport crossing brain barrier systems by Cu-ATPases: effect of manganese exposure. Toxicol Sci. 2014;139:432–451.
   PubMed Web of Science ®Google Scholar
• Walshe JM. Wilson’s disease. Br Med J (Clin Res Ed). 1984;288:1689.
   PubMedGoogle Scholar
• Olivarez L, Caggana M, Pass KA, et al. Estimate of the frequency of Wilson’s disease in the US Caucasian population: a mutation analysis approach. Ann Hum Genet. 2001;65:459–463.
   PubMed Web of Science ®Google Scholar
• Olsson C, Waldenström E, Westermark K, et al. Determination of the frequencies of ten allelic variants of the Wilson disease gene (ATP7B), in pooled DNA samples. Eur J Hum Genet. 2000;8:933–938.
   PubMed Web of Science ®Google Scholar
• Hahn SH, Lee SY, Jang Y-J, et al. Pilot study of mass screening for Wilson’s disease in Korea. Mol Genet Metab. 2002;76:133–136.
   PubMed Web of Science ®Google Scholar
• Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson’s disease in the United Kingdom. Brain. 2013;136:1476–1487.
   PubMed Web of Science ®Google Scholar
• Kenney SM, Cox DW. Sequence variation database for the Wilson disease copper transporter, ATP7B. Hum Mutat. 2007;28:1171–1177.
   PubMed Web of Science ®Google Scholar
• Caca K, Ferenci P, Kühn HJ, et al. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol. 2001;35:575–581.
   PubMed Web of Science ®Google Scholar
• Gromadzka G, Schmidt HHJ, Genschel J, et al. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson’s disease. Mov Disord. 2006;21:245–248.
   PubMed Web of Science ®Google Scholar
• Mihaylova V, Todorov T, Jelev H, et al. Neurological symptoms, genotype-phenotype correlations and ethnic-specific differences in Bulgarian patients with Wilson disease. Neurologist. 2012;18:184–189.
   PubMed Web of Science ®Google Scholar
• Mordaunt CE, Shibata NM, Kieffer DA, et al. Epigenetic changes of the thioredoxin system in the tx-j mouse model and in patients with Wilson disease. Hum Mol Genet. 2018;27:3854–3869.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Członkowska A, Merle U, et al. Late-onset Wilson’s disease. Gastroenterology. 2007;132:1294–1298.
   PubMed Web of Science ®Google Scholar
• Ala A, Borjigin J, Rochwarger A, et al. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology. 2005;41:668–670.
   PubMed Web of Science ®Google Scholar
• Saito T. Presenting symptoms and natural history of Wilson disease. Eur J Pediatr. 1987;146:261–265.
   PubMed Web of Science ®Google Scholar
• Roberts EA. Update on the diagnosis and management of Wilson disease. Curr Gastroenterol Rep. 2018;20:56.
   PubMedGoogle Scholar
• Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089–2111.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Stremmel W, Członkowska A, et al. Age and sex but not ATP7B genotype effectively influence the clinical phenotype of Wilson disease. Hepatology. 2019;69:1464–1476.
   PubMed Web of Science ®Google Scholar
• Dusek P, Litwin T, Czlonkowska A. Wilson disease and other neurodegenerations with metal accumulations. Neurol Clin. 2015;33:175–204.
   PubMed Web of Science ®Google Scholar
• O’Halloran TV, Culotta VC. Metallochaperones, an intracellular shuttle service for metal ions. J Biol Chem. 2000;275:25057–25060.
   PubMed Web of Science ®Google Scholar
• Cruces-Sande A, Rodríguez-Pérez AI, Herbello-Hermelo P, et al. Copper increases brain oxidative stress and enhances the ability of 6-hydroxydopamine to cause dopaminergic degeneration in a rat model of Parkinson’s disease. Mol Neurobiol. 2019;56:2845–2854.
   PubMed Web of Science ®Google Scholar
• Członkowska A, Litwin T, Dzieżyc K, et al. Characteristics of a newly diagnosed polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson’s disease rating scale. BMC Neurol. 2018;18:34.
   PubMed Web of Science ®Google Scholar
• Hedera P. Wilson’s disease: A master of disguise. Parkinsonism Relat Disord. 2019;59:140–145.
   PubMed Web of Science ®Google Scholar
• Lorincz MT. Neurologic Wilson’s disease. Ann N Y Acad Sci. 2010;1184:173–187.
   PubMed Web of Science ®Google Scholar
• Hedera P. Update on the clinical management of Wilson’s disease. 2017; 10:9–19.
   Google Scholar
• Iwański S, Seniów J, Leśniak M, et al. Diverse attention deficits in patients with neurologically symptomatic and asymptomatic Wilson’s disease. Neuropsychology. 2015;29:25–30.
   PubMed Web of Science ®Google Scholar
• Rosen H. Dextromethorphan/quinidine sulfate for pseudobulbar affect. Drugs Today (Barc). 2008;44:661–668.
   PubMed Web of Science ®Google Scholar
• Carta M, Mura G, Sorbello O, et al. Quality of life and psychiatric symptoms in Wilson’s disease: the relevance of bipolar disorders. Clin Pract Epidemiol Ment Health. 2012;8:102–109.
   PubMedGoogle Scholar
• Zimbrean PC, Schilsky ML. Psychiatric aspects of Wilson disease: a review. Gen Hosp Psychiatry. 2014;36:53–62.
   PubMed Web of Science ®Google Scholar
• Prashanth LK, Taly AB, Sinha S, et al. Wilson’s disease: diagnostic errors and clinical implications. J Neurol Neurosurg Psychiatry. 2004;75:907–909.
   PubMed Web of Science ®Google Scholar
• Soltanzadeh A, Soltanzadeh P, Nafissi S, et al. Wilson’s disease: A great masquerader. Eur Neurol. 2007;57:80–85.
   PubMed Web of Science ®Google Scholar
• Medici V, Trevisan CP, D’Incà R, et al. Diagnosis and management of Wilson’s disease: results of a single center experience. J Clin Gastroenterol. 2006;40:936–941.
   PubMed Web of Science ®Google Scholar
• Lowette KF, Desmet K, Witters P, et al. Wilson’s disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine. Eur J Gastroenterol Hepatol. 2010;22:564–571.
   PubMed Web of Science ®Google Scholar
• Srinivas K, Sinha S, Taly AB, et al. Dominant psychiatric manifestations in Wilson’s disease: a diagnostic and therapeutic challenge! J Neurol Sci. 2008;266:104–108.
   PubMed Web of Science ®Google Scholar
• Mura G, Zimbrean PC, Demelia L, et al. Psychiatric comorbidity in Wilson’s disease. Int Rev Psychiatry. 2017;29:445–462.
   PubMed Web of Science ®Google Scholar
• Sahu JK, Singhi P, Malhotra S. Late occurrence of isolated obsessive-compulsive behavior in a boy with Wilson’s disease on treatment. J Child Neurol. 2013;28:277.
   PubMed Web of Science ®Google Scholar
• Kumawat BL, Sharma CM, Tripathi G, et al. Wilson’s disease presenting as isolated obsessive-compulsive disorder. Indian J Med Sci. 2007;61:607–610.
   PubMedGoogle Scholar
• Nevsimalova S, Buskova J, Bruha R, et al. Sleep disorders in Wilson’s disease. Eur J Neurol. 2011;18:184–190.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Czlonkowska A, Stremmel W, et al. EASL clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56:671–685.
   PubMed Web of Science ®Google Scholar
• Shanmugiah A, Sinha S, Taly DA, et al. Psychiatric manifestations in Wilson’s disease: a cross-sectional analysis. J Neuropsychiatry Clin Neurosci. 2008;20:81–85.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease1. Liver Int. 2003;23:139–142.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Wilson disease. Contin Lifelong Learn Neurol. 2016;22:1246–1261.
   Google Scholar
• Ala A, Walker AP, Ashkan K, et al. Wilson’s disease. Lancet. 2007;369:397–408.
   PubMed Web of Science ®Google Scholar
• Nicastro E, Ranucci G, Vajro P, et al. Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease. Hepatology. 2010;52:1948–1956.
   PubMed Web of Science ®Google Scholar
• Merle U, Weiss KH, Eisenbach C, et al. Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease. 2010;10:8.
   Google Scholar
• Kaler SG, Holmes CS, Goldstein DS, et al. Neonatal diagnosis and treatment of menkes disease. N Engl J Med. 2008;358:605–614.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Castro KI, Hevia-Urrutia FJ, Sturniolo GC. Wilson’s disease: A review of what we have learned. World J Hepatol. 2015;7:2859–2870.
   PubMed Web of Science ®Google Scholar
• Sinha S, Taly AB, Ravishankar S, et al. Wilson’s disease: cranial MRI observations and clinical correlation. Neuroradiology. 2006;48:613–621.
   PubMed Web of Science ®Google Scholar
• Hermann W. Morphological and functional imaging in neurological and non-neurological Wilson’s patients. Ann N Y Acad Sci. 2014;1315:24–29.
   PubMed Web of Science ®Google Scholar
• Fritzsch D, Reiss-Zimmermann M, Trampel R, et al. Seven-tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation. Invest Radiol. 2014;49:299–306.
   PubMed Web of Science ®Google Scholar
• Litwin T, Dzieżyc K, Karliński M, et al. Early neurological worsening in patients with Wilson’s disease. J Neurol Sci. 2015;355:162–167.
   PubMed Web of Science ®Google Scholar
• Gh Popescu BF, Nichol H. Mapping brain metals to evaluate therapies for neurodegenerative disease. CNS Neurosci Ther. 2011;17:256–268.
   PubMed Web of Science ®Google Scholar
• Masełbas W, Chabik G, Członkowska A. Persistence with treatment in patients with Wilson disease. Neurol Neurochir Pol. 2010;44:260–263.
   PubMed Web of Science ®Google Scholar
• Burke JF, Dayalu P, Nan B, et al. Prognostic significance of neurologic examination findings in Wilson disease. Parkinsonism Relat Disord. 2011;17:551–556.
   PubMed Web of Science ®Google Scholar
• Chahine LM, Chemali ZN. The bane of a silent illness: when Wilson’s disease takes its course. Int J Psychiatry Med. 2006;36:333–338.
   PubMed Web of Science ®Google Scholar
• Zimbrean PC, Schilsky ML. The spectrum of psychiatric symptoms in Wilson’s disease: treatment and prognostic considerations. Am J Psychiatry. 2015;172:1068–1072.
   PubMed Web of Science ®Google Scholar
• Kulaksizoglu IB, Polat A. Quetiapine for Mania with Wilson’s disease. Psychosomatics. 2003;44:438–439.
   PubMed Web of Science ®Google Scholar
• Weiss KH, Thurik F, Gotthardt DN, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol. 2013;11:1028–1035.e2.
   PubMed Web of Science ®Google Scholar
• Tremmel R, Uhl P, Helm F, et al. Delivery of Copper-chelating trientine (TETA) to the central nervous system by surface modified liposomes. Int J Pharm. 2016;512:87–95.
   PubMedGoogle Scholar
• Bonda DJ, Liu G, Men P, et al. Nanoparticle delivery of transition-metal chelators to the brain: oxidative stress will never see it coming! CNS neurol. Disord - Drug Targets. 2012;11:81–85.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Terry CA, Aisen AM, et al. Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch Neurol. 1987;44:490–493.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Bhatt M. Advances in treatment of Wilson disease. Tremor Other Hyperkinet Mov (N Y). 2018;8:525.
   PubMed Web of Science ®Google Scholar
• Durand F, Bernuau J, Giostra E, et al. Wilson’s disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine. Gut. 2001;48:849–852.
   PubMed Web of Science ®Google Scholar
• Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol. 2015;14:103–113.
   PubMed Web of Science ®Google Scholar
• Członkowska A, Litwin T, Karliński M, et al. D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol. 2014;21:599–606.
   PubMed Web of Science ®Google Scholar
• Nagral A, Sarma MS, Matthai J, et al. Wilson’s disease: clinical practice guidelines of the Indian National association for study of the liver, the Indian society of pediatric gastroenterology, hepatology and nutrition, and the movement disorders society of India. J Clin Exp Hepatol. 2019;9:74–98.
   PubMed Web of Science ®Google Scholar
• Weiss KH, Askari FK, Czlonkowska A, et al. Bis-choline tetrathiomolybdate in patients with Wilson’s disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol. 2017;2:869–876.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 2003;60:379–385.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006;63:521–527.
   PubMed Web of Science ®Google Scholar
• Roberts EA, Schilsky ML. AASLD Practice guidelines diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089–2111.
   Google Scholar
• EASL Clinical Practice Guidelines: Wilson's disease, J Hepatol. 2012; 56:671-85.
   Google Scholar
• Yuzbasiyan-Gurkan V, Grider A, Nostrant T, et al. Treatment of Wilson’s disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med. 1992;120:380–386.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson’s disease with zinc: XV long-term follow-up studies. J Lab Clin Med. 1998;132:264–278.
   PubMed Web of Science ®Google Scholar
• Linn FHH, Houwen RHJ, van Hattum J, et al. Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. Hepatology. 2009;50:1442–1452.
   PubMed Web of Science ®Google Scholar
• Weiss KH, Gotthardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology. 2011;140:1189–1198.e1.
   PubMed Web of Science ®Google Scholar
• Ranucci G, Di Dato F, Spagnuolo M, et al. Zinc monotherapy is effective in Wilson’s disease patients with mild liver disease diagnosed in childhood: a retrospective study. Orphanet J Rare Dis. 2014;9:41.
   PubMed Web of Science ®Google Scholar
• Hefter H, Tezayak O, Rosenthal D. Long-term outcome of neurological Wilson’s disease. Parkinsonism Relat Disord. 2018;49:48–53.
   PubMed Web of Science ®Google Scholar
• Loganathan S, Nayak R, Sinha S, et al. Treating Mania in Wilson’s disease with lithium. J Neuropsychiatr. 2008;20:487–489.
   PubMed Web of Science ®Google Scholar
• Rybakowski JK, Litwin T, Chlopocka-Wozniak M, et al. Lithium treatment of a bipolar patient with Wilson’s disease: a case report. Pharmacopsychiatry. 2013;46:120–121.
   PubMed Web of Science ®Google Scholar
• Woerwag-Mehta S, Hindley P, Hedderly T, et al. Complex psychiatric presentation in adolescent onset Wilson’s disease. BMJ Case Rep. 2011;2011:bcr0120102628–bcr0120102628.
   PubMedGoogle Scholar
• Litwin T, Dzieżyc K, Karliński M, et al. Psychiatric disturbances as a first clinical symptom of Wilson’s disease - case report. Psychiatr Pol. 2016;50:337–344.
   PubMed Web of Science ®Google Scholar
• Litwin T, Dusek P, Szafrański T, et al. Psychiatric manifestations in Wilson’s disease: possibilities and difficulties for treatment. Ther Adv Psychopharmacol. 2018;8:199–211.
   PubMed Web of Science ®Google Scholar
• Shah H, Vankar GK. Wilson’s disease: a case report. Indian J Psychiatry. 2003;45:253–254.
   PubMedGoogle Scholar
• Eggers B, Hermann W, Barthel H, et al. The degree of depression in Hamilton rating scale is correlated with the density of presynaptic serotonin transporters in 23 patients with Wilson’s disease. J Neurol. 2003;250:576–580.
   PubMed Web of Science ®Google Scholar
• Litwin T, Chabik G, Członkowska A. Acute focal dystonia induced by a tricyclic antidepressant in a patient with Wilson disease: a case report. Neurol Neurochir Pol. 2013;47:502–506.
   PubMed Web of Science ®Google Scholar
• Rodrigues ACT, Dalgalarrondo P, Banzato CEM. Successful ECT in a patient with a psychiatric presentation of Wilson’s disease. J Ect. 2004;20:55.
   PubMed Web of Science ®Google Scholar
• Avasthi A, Sahoo M, Modi M, et al. Psychiatric manifestations of wilson′s disease and treatment with electroconvulsive therapy. Indian J Psychiatry. 2010;52:66.
   PubMedGoogle Scholar
• Vaishnav P, Gandhi H. Electro convulsive therapy in psychiatric manifestations in Wilson′s disease. Indian J Psychol Med. 2013;35:206.
   PubMedGoogle Scholar
• Faden J, O’Reardon JP. Dextromethorphan/quinidine for neuropsychiatric manifestations of Wilson’s disease. Prim Care Companion CNS Disord. 2015; 17(6):10.
   Google Scholar
• Hölscher S, Leinweber B, Hefter H, et al. Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease. Eur Neurol. 2010;64:83–87.
   PubMed Web of Science ®Google Scholar
• Sorbello O, Riccio D, Sini M, et al. Resolved psychosis after liver transplantation in a patient with Wilson’s disease. Clin Pract Epidemiol Ment Health. 2011;7:182–184.
   PubMedGoogle Scholar
• Sutcliffe RP, Maguire DD, Muiesan P, et al. Liver transplantation for Wilson’s disease: long-term results and quality-of-life assessment. Transplantation. 2003;75:1003–1006.
   PubMed Web of Science ®Google Scholar
• Medici V, Mirante VG, Fassati LR, et al. Liver transplantation for Wilson’s disease: the burden of neurological and psychiatric disorders. Liver Transpl. 2005;11:1056–1063.
   PubMed Web of Science ®Google Scholar
• Dubbioso R, Ranucci G, Esposito M, et al. Subclinical neurological involvement does not develop if Wilson’s disease is treated early. Parkinsonism Relat Disord. 2016;24:15–19.
   PubMed Web of Science ®Google Scholar
• Chroni E, Lekka NP, Tsibri E, et al. Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson’s disease. J Neuropsychiatry Clin Neurosci. 2001;13:531–532.
   PubMed Web of Science ®Google Scholar
• Mordaunt CE, Kieffer DA, Shibata NM, et al. Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers. Epigenetics Chromatin.2019;12:10.
   Web of Science ®Google Scholar
• Sarode GV, Kim K, Kieffer DA, et al. Metabolomics profiles of patients with Wilson disease reveal a distinct metabolic signature. Metabolomics. 123AD. 2019;15:43.
   PubMed Web of Science ®Google Scholar
• Ranucci G, Polishchuck R, Iorio R. Wilson’s disease: prospective developments towards new therapies. World J Gastroenterol. 2017;23:5451.
   PubMed Web of Science ®Google Scholar